Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada.
Division of Nephrology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada.
Am J Transplant. 2020 Nov;20(11):3221-3224. doi: 10.1111/ajt.16089. Epub 2020 Jun 24.
The novel coronavirus disease 2019 (COVID-19) is associated with increased risk of thromboembolic events, but the extent and duration of this hypercoagulable state remain unknown. We describe the first case report of renal allograft infarction in a 46-year-old kidney-pancreas transplant recipient with no prior history of thromboembolism, who presented 26 days after diagnosis of COVID-19. At the time of renal infarct, he was COVID-19 symptom free and repeat test for SARS-CoV-2 was negative. This case report suggests that a hypercoagulable state may persist even after resolution of COVID-19. Further studies are required to determine thromboprophylaxis indications and duration in solid organ transplant recipients with COVID-19.
2019 年新型冠状病毒病（COVID-19）与血栓栓塞事件的风险增加相关，但这种高凝状态的程度和持续时间尚不清楚。我们描述了首例 COVID-19 诊断后 26 天发生的肾移植受者肾移植梗死的病例报告，该受者无血栓栓塞病史。在发生肾梗死时，他没有 COVID-19 症状，且 SARS-CoV-2 重复检测为阴性。本病例报告表明，高凝状态甚至在 COVID-19 痊愈后仍可能持续存在。需要进一步研究来确定 COVID-19 患者中实体器官移植受者的血栓预防指征和持续时间。
